BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alicea GM, Rebecca VW. Emerging strategies to treat rare and intractable subtypes of melanoma. Pigment Cell Melanoma Res 2021;34:44-58. [PMID: 32274887 DOI: 10.1111/pcmr.12880] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Broit N, Johansson PA, Rodgers CB, Walpole ST, Hayward NK, Pritchard AL. Systematic review and meta-analysis of genomic alterations in acral melanoma. Pigment Cell Melanoma Res 2022;35:369-86. [PMID: 35229492 DOI: 10.1111/pcmr.13034] [Reference Citation Analysis]
2 Alicea GM, Rebecca VW. Un-Fair Skin: racial disparities in acral melanoma research. Nat Rev Cancer 2022;22:127-8. [PMID: 35075287 DOI: 10.1038/s41568-022-00443-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Al Mahi A, Ablain J. RAS pathway regulation in melanoma. Dis Model Mech 2022;15:dmm049229. [PMID: 35234863 DOI: 10.1242/dmm.049229] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Qian J, Ding W, Jiang Y, Xu L. Meta-Analysis of irAEs between Dose of CTLA-4 and PD-1 Inhibitors. 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 2021. [DOI: 10.1109/bibm52615.2021.9669586] [Reference Citation Analysis]
5 Ma Y, Xia R, Ma X, Judson-Torres RL, Zeng H. Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy. Front Oncol 2021;11:702287. [PMID: 34350118 DOI: 10.3389/fonc.2021.702287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Safi M, Trapani D, Alradhi M, Shan X, Jiwei L. No Overall Survival Difference in the Immunotherapy Era for Rare Subtypes of Melanoma. Pathol Oncol Res 2021;27:639004. [PMID: 34257604 DOI: 10.3389/pore.2021.639004] [Reference Citation Analysis]
7 Han A, Schug ZT, Aplin AE. Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma. Trends Cancer 2021;7:671-81. [PMID: 34127435 DOI: 10.1016/j.trecan.2021.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 González-Ruiz L, González-Moles MÁ, González-Ruiz I, Ruiz-Ávila I, Ramos-García P. Prognostic and Clinicopathological Significance of CCND1/Cyclin D1 Upregulation in Melanomas: A Systematic Review and Comprehensive Meta-Analysis. Cancers (Basel) 2021;13:1314. [PMID: 33804108 DOI: 10.3390/cancers13061314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
9 Roy T, Boateng ST, Banang-Mbeumi S, Singh PK, Basnet P, Chamcheu RN, Ladu F, Chauvin I, Spiegelman VS, Hill RA, Kousoulas KG, Nagalo BM, Walker AL, Fotie J, Murru S, Sechi M, Chamcheu JC. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers. Bioorg Chem 2021;107:104595. [PMID: 33450548 DOI: 10.1016/j.bioorg.2020.104595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
10 Teterycz P, Czarnecka AM, Indini A, Spałek MJ, Labianca A, Rogala P, Cybulska-Stopa B, Quaglino P, Ricardi U, Badellino S, Szumera-Ciećkiewicz A, Falkowski S, Mandala M, Rutkowski P. Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. Cancers (Basel) 2020;12:E3131. [PMID: 33114734 DOI: 10.3390/cancers12113131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
11 Ren C, Ruan Y. Expression and clinical significance of five major genes in cutaneous melanoma based on TCGA database. Human Pathology: Case Reports 2020;21:200411. [DOI: 10.1016/j.ehpc.2020.200411] [Reference Citation Analysis]